Let's talk about Elan
Wide product lines and deep pipelines are a blessing, but that's not the only way to win the game. I saw Amgen
And maybe having a diversified drug portfolio is overrated. As big as Pfizer
So where does that leave us when it comes to Elan? Well, we're not all in agreement. Anders Bylund is feeling bullish about the drug maker's chances, while Brian Lawler is donning his flame-retardant suit to tackle the bearish case.
Who will win? It's Elan's story, now.
- Read the bull argument.
- Read the bear argument.
- Read the bullish rebuttal.
- Read the bearish rebuttal.
- Sound off in Motley Fool CAPS.
- Vote for the winner.